Want to see HAO full AI Analyst Report?
Haoxi Health Technology Limited Class A (HAO) AI Stock Analysis
Haoxi Health Technology Limited Class A
(NASDAQ:HAO)
The overall score reflects a combination of strong valuation, with the stock appearing undervalued, and moderate financial performance, highlighted by revenue growth but hampered by cash flow issues. Technical analysis indicates a lack of strong momentum, contributing to the overall risk profile.
Haoxi Health Technology Limited Class A (HAO) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $672.45K
- Dividend Yield
- ―
- Average Volume (3M)
- 191.88K
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- 2.10
- Revenue Growth
- 67.14%
- EPS Growth
- -270.67%
- Country
- US
- Employees
- 28
- Sector
- Communication Services
- Sector Strength
- 60
- Industry
- Advertising Agencies
Haoxi Health Technology Limited Class A Business Overview & Revenue Model
Company Description
Haoxi Health Technology Limited, operating with its subsidiaries in China, specializes in providing digital marketing services. The company's offerings encompass online short video marketing, which it delivers to advertisers through its network of me...
How the Company Makes Money
Haoxi Health Technology generates revenue through multiple streams, including the sale of medical devices and health monitoring systems directly to healthcare providers and institutions. Additionally, the company offers subscription-based services fo...
Haoxi Health Technology Limited Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HAO, the sentiment is Negative. The current price of 1.92 is below the 20-day moving average (MA) of 2.18, below the 50-day MA of 2.68, and below the 200-day MA of 1182.76, indicating a bearish trend. The MACD of -0.49 indicates Negative momentum. The RSI at 34.01 is Neutral, neither overbought nor oversold. The STOCH value of 58.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HAO.
Haoxi Health Technology Limited Class A Risk Analysis
Haoxi Health Technology Limited Class A disclosed 75 risk factors in its most recent earnings report. Haoxi Health Technology Limited Class A reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksHaoxi Health Technology Limited Class A Peers Comparison
Overall Rating
CHR68Neutral- HAO68Neutral
CNET44Neutral
DRCT40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CHR | 68Neutral | $3.17M | 0.04 | 6.83% | ― | -5.96% | -94.51% |
| HAO | 68Neutral | $1.17M | -0.01 | -56.40% | ― | 67.14% | -270.67% |
| Sector * | 60Neutral | $48.67B | 4.58 | -11.27% | 4.14% | 2.83% | -41.78% |
| CNET | 44Neutral | $3.16M | -2.81 | -20.50% | ― | -55.14% | 86.77% |
| DRCT | 40Underperform | $128.44K | -0.02 | 570.82% | ― | -15.24% | 61.99% |
* Communication Services Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HAO | Haoxi Health Technology Limited Class A | 1.92 | -2634.88 | -99.93% | |
| CNET | Zw Data Action Technologies Inc. | 0.86 | -1.31 | -60.32% | |
| CHR | Cheer Holding, Inc. | 1.35 | -17.52 | -92.85% | |
| BAOS | Baosheng Media Group Holdings Ltd | 0.15 | -2.86 | -95.02% | |
| DRCT | Direct Digital Holdings, Inc. Class A | 0.16 | -79.00 | -99.80% | |
| STFS | Star Fashion Culture Holdings Ltd. Class A | 4.88 | -1.84 | -27.38% |
Haoxi Health Technology Limited Class A Corporate Events
Haoxi Health Technology Approves Major Shareholder Changes at December Meeting
On December 8, 2025, Haoxi Health Technology Limited held an extraordinary general meeting where shareholders approved several significant changes. These included increasing the voting rights of Class B shares from ten to thirty votes, expanding the...
Haoxi Health Technology Secures $5 Million in Private Placement
On November 26, 2025, Haoxi Health Technology Limited entered into a Securities Purchase Agreement with several non-U.S. investors for a private placement of 6,250,000 Class A ordinary shares and 12,500,000 warrants, raising gross proceeds of $5 mill...
Haoxi Health Technology Announces Extraordinary General Meeting for Governance and Capital Changes
Haoxi Health Technology Limited announced an extraordinary general meeting of shareholders scheduled to discuss significant proposals, including increasing the voting rights of Class B shares and expanding the authorized share capital. These changes,...
Haoxi Health Technology Closes $1.2 Million Private Placement
Haoxi Health Technology Limited, a company engaged in the health technology sector, announced the successful closing of a private placement on October 22, 2025. The company sold 5,217,391 Class A ordinary shares at $0.23 per share, raising $1.2 milli...
Haoxi Health Technology Secures $1.2 Million Through Private Placement
On October 13, 2025, Haoxi Health Technology Limited entered into a securities purchase agreement with non-U.S. investors to sell 5,217,391 Class A ordinary shares for approximately $1.2 million. The proceeds from this private placement will be used...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jul 30, 2025